NP 2

Drug Profile

NP 2

Alternative Names: NET-ENK; NP2; NP2 Enkephalin; NTDDS expressing enkephalin; PGN-202

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Diamyd Medical
  • Developer Periphagen Holdings
  • Class Analgesics; Gene therapies
  • Mechanism of Action Enkephalin modulators; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cancer pain; Neuropathic pain

Most Recent Events

  • 12 Apr 2017 Discontinued - Phase-II for Cancer pain in USA (Intradermal) (Periphagen Holdings pipeline, April 2017)
  • 12 Apr 2017 Discontinued - Preclinical for Neuropathic pain USA (Intradermal) (Periphagen Holdings pipeline, April 2017)
  • 01 Nov 2013 Diamyd completes a phase II trial in Cancer pain in USA (NCT01291901)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top